Weiss Ratings Reaffirms "Sell (D-)" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for NRx Pharmaceuticals (NASDAQ: NRXP), indicating ongoing concerns about the company's stock performance.
• NRx Pharmaceuticals experienced a recent trading decline of 2.5%, with a current stock price of $3.58, and a one-year price range between $1.10 and $6.01.
• The company's quarterly earnings report showed a loss of ($0.98) EPS, significantly missing analyst expectations, with forecasts predicting a total annual EPS of (-1.75).

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

NRXP has been the topic of a number of other research reports. D. Boral Capital restated a "buy" rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, September 25th. BTIG Research restated a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a report on Wednesday, October 1st. Finally, Zacks Research upgraded NRx Pharmaceuticals to a "hold" rating in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, NRx Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $34.50.

NRx Pharmaceuticals Trading Down 2.5%

NASDAQ NRXP opened at $3.58 on Wednesday. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01. The stock has a 50-day moving average of $2.81 and a 200-day moving average of $2.68. The firm has a market cap of $70.92 million, a PE ratio of -1.60 and a beta of 1.74.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). As a group, equities research analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in NRXP. Millennium Management LLC bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $61,000. Geode Capital Management LLC boosted its position in shares of NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, Anson Funds Management LP boosted its position in shares of NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock worth $2,417,000 after purchasing an additional 993,401 shares in the last quarter. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.